Other

Pfizer 3Q net falls due to generics, higher costs

Pfizer Inc.'s third-quarter profit dropped 19 percent as competition from generic drugs continued to cut sales, while lower operating expenses failed to offset higher taxes and charges.

Diseases, Conditions, Syndromes

Program to up access to combo malaria therapy successful

(HealthDay)—Implementation of a series of national-scale pilot programs designed to increase the access and use of quality-assured artemisinin-based combination therapies (QAACTs) for malaria by the Affordable Medicines ...

Other

Amgen misses 1Q views as higher costs cut profit

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed Wall Street's ...

Other

AbbVie hikes forecast, tops Street expectations

The drugmaker AbbVie surprised Wall Street on Friday with a third-quarter performance that turned out much better than expected and a new 2014 forecast that also extends well beyond what analysts predict.

Other

Royalty Pharma lets Elan takeover bid expire

Royalty Pharma has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.

Medical economics

Pfizer to buy Array BioPharma in deal worth $11.4 billion

Pfizer is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma, a drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring.

page 17 from 20